Coherus Oncology, Inc.

CHRS · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders19.1%

Institutions37.4%

Public / Other

	You	Peer avg
Revenue Growth	+39.5%	+260.6%
ROE	-178.4%	-61.4%

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$42.17M	$266.96M	$257.24M	$211.04M	$326.55M	$475.82M	$356.07M	$0	$1.56M	$630000
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$13.81M	$117.55M	$158.99M	$70.08M	$57.59M	$37.67M	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$181.13M	-$111.67M	-$203.20M	-$256.88M	-$263.86M	$156.32M	$107.77M	-$204.42M	-$232.14M	-$115.93M
Operating income as a percentage of revenue.	-429.5%	-41.8%	-79.0%	-121.7%	-80.8%	32.9%	30.3%	–	-14918.8%	-18401.7%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$168.02M	$28.51M	-$237.89M	-$291.75M	-$287.10M	$132.24M	$0	-$70000	-$116000	-$451000
Net income divided by the number of shares outstanding — profit attributable to each share.	$1.43	$0.25	$-2.00	$-3.76	$-3.81	$1.85	$1.29	$-3.00	$-4.00	$-3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$1.00	$0.25	$-2.00	$-3.76	$-3.81	$1.62	$1.23	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$88.88M	$125.99M	$102.89M	$63.55M	$417.19M	$541.16M	$177.67M	$72.36M	$126.91M	$124.95M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$258.34M	$448.53M	$629.60M	$480.85M	$679.33M	–	$408.93M	$99.47M	$162.61M	$178.49M
Everything the company owes — debt, unpaid bills, and other obligations.	$197.33M	$580.52M	$823.03M	$618.26M	$581.61M	–	$303.71M	$138.06M	$132.08M	$159.13M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$61.01M	-$131.99M	-$193.43M	-$137.42M	$97.73M	–	$105.21M	-$38.59M	$31.82M	$20.53M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$138.51M	-$20.44M	-$174.88M	-$241.12M	-$37.43M	$154.15M	$28.36M	-$159.27M	-$200.29M	-$252.54M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	–	$286000	$2.04M	$1.29M	$7.23M	$1.82M	$789000	$4.57M	$6.51M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	–	-$175.17M	-$243.16M	-$38.72M	$146.91M	$26.53M	-$160.06M	-$204.86M	-$259.06M

Coherus Oncology, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Peer Comparison

Income Statement

Balance Sheet

Cash Flow Statement